Todd Blanche is drawing attention after telling senators he wants the government to move harder against abortion pills sent through the mail. His comments put a fresh spotlight on the Trump administration’s approach to abortion enforcement, especially with federal law, agency review, and political promises all pulling in different directions.
During confirmation testimony, Blanche made clear he sees mail-order abortion drugs as a serious problem. He described images of pills arriving in loose packaging, sometimes from overseas, and said the practice is wrong, adding, “I very much commit our resources to stopping this.”
That stance goes beyond the softer position President Donald Trump and Vice President JD Vance have taken so far. Trump said during the 2024 campaign that he would not bring back the restrictions Joe Biden rolled back, and Vance had signaled the same view before joining the ticket.
Blanche also drew a line between his position and the Biden administration’s record. He said the prior White House was not being defended, pointing to Biden-era decisions that removed the in-person dispensing requirement for the abortion pill and stopped enforcement of the federal ban on mailing abortifacients.
At the same time, he stopped short of promising an immediate crackdown. Instead, he leaned on the administration’s ongoing safety review of abortion pill data, which federal health officials are still examining before putting out their findings later in the year.
That review is now part of a larger legal and political standoff. Blanche said the administration wants a result that matches Trump’s priorities, but he also suggested the process needs to run its course before the government makes a final move on the rules.
His answer came as senators pressed him on Louisiana’s lawsuit against the Justice Department. The DOJ is still defending the Biden policy, arguing that the review should continue without being interrupted by court pressure or outside demands.
For abortion opponents, the issue is bigger than one review. They argue that mail delivery has become the easiest way to sidestep state restrictions, making it possible to keep abortion access alive even in places with tight limits or near-total bans.
That matters because the map is already split hard. Thirteen states ban most abortions starting at conception, five more restrict the procedure once a fetal heartbeat is detected, and other states have their own limits layered on top of that.
Mail-order pills have become the abortion industry’s workaround. They allow a procedure that would otherwise run into state laws to be delivered quietly and quickly, often without the kind of in-person oversight that critics say should be required.
The latest abortion numbers are also feeding the debate. Pro-abortion Guttmacher Institute data pointed to 1,125,930 clinical abortions in 2025, a slight rise from the year before, with the organization tying much of that increase to pills.
Planned Parenthood’s own annual report adds more fuel to the fire. It says the group carried out 434,450 abortions in 2024-2025, which the report describes as a record and an 8% jump from the previous year.
Supporters of tighter enforcement say the safety case is just as important as the legal one. They point to research from the Ethics & Public Policy Center that found nearly 11% of women experienced sepsis, infection, hemorrhaging, or another major complication after taking mifepristone, based on insurance data.
Other researchers have raised similar alarms. A separate analysis from the Restoration of America Foundation reached comparable conclusions and described a growing pattern of risks that it says has been minimized in public debate.
That is why many pro-life advocates say the administration should not wait around for perfect timing. In their view, the law already prohibits mailing abortion-inducing drugs, and Biden’s refusal to enforce that rule was a political choice made in response to the fall of Roe v. Wade, not a new medical judgment.
